Product Description
CPB536 is a 2+2 tetravalent trispecific designed to simultaneously target mouse programmed cell death 1 ligand 1 (PD-L1, CD274, B7-H1), mouse T cell immunoreceptor with Ig and ITIM domains (TIGIT) and mouse lymphocyte-activation gene 3 (LAG3). CPB536 features monovalent binding to mouse TIGIT and mouse LAG3, with bivalent binding to mouse PD-L1. This trispecific was designed to bind antigens on different cells, bridging tumor/APCs with T cells. PD-L1 blockade prevents PD-1/PD-L1 suppression and provides tumor/APC anchoring, TIGIT blockade relieves TIGIT-mediated inhibitory signaling on dysfunctional T cells and LAG-3 blockade relieves a second major exhaustion pathway, improving T-cell activation and expansion. Fc-competent PD-L1 * TIGIT * LAG-3 trispecifics simultaneously block three inhibitory axes to promote tumor-localized T-cell engagement, leading to stronger anti-tumor T-cell responses.
* VAT and shipping costs not included. Errors and price changes excepted
